Cardio-facio-cutaneous syndrome: genes and variants
Explore variant evidence for Cardio-facio-cutaneous syndrome across 4 analyzed proteins (BRAF, MAP2K1, KRAS, MAP2K2). Linked ClinVar records include 38 pathogenic or likely pathogenic variants, 0 variants of uncertain significance and 2 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Cardio-facio-cutaneous syndrome
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
26 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in BRAF have source records linked to Cardio-facio-cutaneous syndrome. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
6 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K1 have source records linked to Cardio-facio-cutaneous syndrome. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
4 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in KRAS have source records linked to Cardio-facio-cutaneous syndrome. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
2 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K2 have source records linked to Cardio-facio-cutaneous syndrome. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): PTPN11.
Where Cardio-facio-cutaneous syndrome variants cluster
- BRAF Protein kinase (positions 457–717): 17 of 24 ClinVar pathogenic / likely pathogenic variants, 2.1× more than its size predicts (a length-based count, not a validated hotspot).
- BRAF Phorbol-ester/DAG-type (positions 234–280): 7 of 24 ClinVar pathogenic / likely pathogenic variants, 4.8× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Cardio-facio-cutaneous syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| MAP2K1 Y130C | 130 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF N581D | 581 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| MAP2K1 Y130H | 130 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| MAP2K2 F57V | 57 | Pathogenic / likely pathogenic (★★★) | |
| BRAF Q257R | 257 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| BRAF T244P | 244 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| KRAS G60R | 60 | Pathogenic / likely pathogenic (★★★) | |
| MAP2K1 D67N | 67 | Pathogenic / likely pathogenic (★★★) | |
| MAP2K2 E207K | 207 | Protein kinase | Pathogenic / likely pathogenic (★★★) |
| BRAF A246P | 246 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| BRAF T241M | 241 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★) |
| BRAF T241P | 241 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★) |
| BRAF E501G | 501 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF E501V | 501 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF N581K | 581 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF Q257K | 257 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★) |
| BRAF F468S | 468 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF G469R | 469 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF A481E | 481 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF K483Q | 483 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF V487G | 487 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF G534R | 534 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF F595L | 595 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF L597V | 597 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| MAP2K1 G128V | 128 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF Q262P | 262 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★) |
| BRAF D565E | 565 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF F635L | 635 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| KRAS I36M | 36 | Effector region | Pathogenic / likely pathogenic (★★) |
| KRAS Y71D | 71 | Pathogenic / likely pathogenic (★★) | |
| KRAS F156I | 156 | Pathogenic / likely pathogenic (★★) | |
| MAP2K1 P124L | 124 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF E501Q | 501 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF H574Y | 574 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF H540Y | 540 | Protein kinase | Pathogenic / likely pathogenic (★) |
| BRAF T470P | 470 | Protein kinase | Pathogenic / likely pathogenic |
| BRAF D594E | 594 | Protein kinase | Pathogenic / likely pathogenic |
| MAP2K1 Q46L | 46 | Pathogenic / likely pathogenic |
Which prediction tools work for Cardio-facio-cutaneous syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 96 out of 100
- MutPred: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 90 out of 100
- SIFT: 87 out of 100
- PolyPhen-2: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 77 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 75 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 69 out of 100
- DMS / MaveDB: 67 out of 100
Same protein, different disease
- RASopathy also has ClinVar records linked to BRAF variants; they fall in the same places as the Cardio-facio-cutaneous syndrome variants (36 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Cardio-facio-cutaneous syndrome variants (17 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Cardio-facio-cutaneous syndrome variants (11 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to BRAF variants; they fall in the same places as the Cardio-facio-cutaneous syndrome variants (10 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to BRAF variants; they fall in the same places as the Cardio-facio-cutaneous syndrome variants (9 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to MAP2K1 variants; they fall mostly in different places as the Cardio-facio-cutaneous syndrome variants (14 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to MAP2K1 variants; they fall partly in the same places as the Cardio-facio-cutaneous syndrome variants (14 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Cardio-facio-cutaneous syndrome variants (23 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Cardio-facio-cutaneous syndrome variants (16 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Cardio-facio-cutaneous syndrome variants (9 pathogenic / likely pathogenic).
- Autoimmune lymphoproliferative syndrome also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Cardio-facio-cutaneous syndrome variants (5 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Cardio-facio-cutaneous syndrome variants (5 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to MAP2K2 variants; they fall mostly in different places as the Cardio-facio-cutaneous syndrome variants (9 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to MAP2K2 variants; they fall partly in the same places as the Cardio-facio-cutaneous syndrome variants (9 pathogenic / likely pathogenic).
Diseases related to Cardio-facio-cutaneous syndrome
- RASopathy, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Noonan syndrome, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Noonan syndrome and Noonan-related syndrome, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Cardiofaciocutaneous syndrome, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Hypertrophic cardiomyopathy, also linked to BRAF, MAP2K1 and MAP2K2
- Non-small cell lung carcinoma, also linked to BRAF, KRAS and MAP2K1
- Costello syndrome, also linked to BRAF, MAP2K1 and MAP2K2
- Vascular malformation, also linked to BRAF, KRAS and MAP2K1
- Melanoma, also linked to BRAF, MAP2K1 and MAP2K2
- Neurofibromatosis, also linked to MAP2K1 and MAP2K2
- Colorectal cancer, also linked to BRAF and KRAS
- Multiple myeloma, also linked to BRAF and KRAS
Frequently asked questions
Which genes have records linked to Cardio-facio-cutaneous syndrome?
This view contains 4 analyzed proteins: BRAF, MAP2K1, KRAS, MAP2K2. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 38 pathogenic or likely pathogenic variants, 0 variants of uncertain significance and 2 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 41 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center